Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
67,129,058
-
Total 13F shares
-
7,418,163
-
Share change
-
+4,340,277
-
Total reported value
-
$16,838,868
-
Price per share
-
$2.27
-
Number of holders
-
32
-
Value change
-
+$9,881,862
-
Number of buys
-
22
-
Number of sells
-
10
Institutional Holders of AIM ImmunoTech Inc. - Common Stock, par value $0.001 per share (AIMI) as of Q1 2021
As of 31 Mar 2021 AIM ImmunoTech Inc. - Common Stock, par value $0.001 per share (AIMI) had 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 7,418,163 shares of stock of the company.
Largest 10 holders included MORGAN STANLEY, VANGUARD GROUP INC, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, Verition Fund Management LLC, CITADEL ADVISORS LLC, and GSA CAPITAL PARTNERS LLP.
This table shows 32 institutional shareholders of the security as of 31 Mar 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.